| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥18856.3B | ¥18386.7B | +2.6% |
| Operating Income | ¥272.3B | ¥298.0B | -8.6% |
| Ordinary Income | ¥293.1B | ¥309.1B | -5.2% |
| Net Income | ¥310.2B | ¥306.8B | +1.1% |
| ROE | 7.7% | 7.5% | - |
FY2025 Q3 cumulative results: Revenue 1,885.6 billion yen (YoY +2.6%), Operating Income 27.2 billion yen (-8.6%), Ordinary Income 29.3 billion yen (-5.2%), Net Income 31.0 billion yen (+1.1%). The company achieved top-line growth while facing operating profit decline, reflecting the low-margin structure inherent in pharmaceutical distribution business. Gross profit margin of 7.7% and operating margin of 1.4% remained at minimal levels. Net income increased slightly due to extraordinary gains from investment securities sales of 14.9 billion yen, which elevated profit before tax to 44.3 billion yen. Basic EPS improved to 439.74 yen from 398.44 yen (YoY +10.4%), supported by extraordinary factors. Balance sheet expanded with total assets reaching 1,307.5 billion yen and cash reserves of 194.7 billion yen, though accounts payable surged 30.2% YoY, indicating working capital management pressures.
Revenue increased 46.9 billion yen YoY to 1,885.6 billion yen, driven primarily by Pharmaceutical Distribution segment which generated 1,782.1 billion yen in external sales (up 2.7% from prior period's 1,735.3 billion yen). Healthcare-Related Services contributed 18.8 billion yen, Regional Medical and Nursing Care Support 70.4 billion yen, Healthcare Product Development 9.0 billion yen, and Specialty Pharmaceutical Distribution Consignment 5.3 billion yen. The segment structure reflects a concentration in pharmaceutical wholesale operations which represent over 94% of total revenue. Operating income declined 25.7 billion yen YoY to 27.2 billion yen, with Pharmaceutical Distribution segment profit falling from 25.2 billion yen to 22.8 billion yen (-9.5%), indicating margin compression in core operations. Cost of sales increased to 1,741.0 billion yen while SG&A expenses reached 117.4 billion yen (6.2% of revenue), together eroding profitability despite revenue growth. Non-operating income provided a net contribution of approximately 2.1 billion yen (ordinary income 29.3 billion yen minus operating income 27.2 billion yen), partially offsetting operational weakness. The gap between ordinary income (29.3 billion yen) and net income (31.0 billion yen) was influenced by extraordinary gains from investment securities sales of 14.9 billion yen, a non-recurring factor that significantly boosted profit before tax to 44.3 billion yen. This represents a revenue up/profit down pattern at the operating level, with extraordinary items supporting final net income growth.
Pharmaceutical Distribution represents the core business with external sales of 1,782.1 billion yen (94.5% of consolidated revenue) and operating income of 22.8 billion yen, delivering an operating margin of 1.3%. This segment experienced profit decline of 9.5% YoY despite revenue growth of 2.7%, indicating intensifying margin pressure in wholesale operations. Healthcare-Related Services generated revenue of 18.8 billion yen and operating income of 0.9 billion yen (4.9% margin), representing improved profitability relative to pharmaceutical distribution. Regional Medical and Nursing Care Support contributed 70.4 billion yen in revenue with operating income of 0.8 billion yen (1.1% margin). Specialty Pharmaceutical Distribution Consignment, newly disclosed as a separate segment due to increased materiality, recorded external sales of 5.3 billion yen and operating income of 0.9 billion yen (16.4% margin), demonstrating notably higher profitability than core distribution. Healthcare Product Development posted revenue of 9.0 billion yen with operating income of 1.8 billion yen (19.9% margin), though profit declined from 2.5 billion yen in the prior period. The segment mix reveals that while pharmaceutical distribution dominates scale, ancillary segments deliver superior margins, highlighting the structural profitability challenge in core wholesale operations.
[Profitability] ROE 7.7% reflects moderate returns supported by financial leverage (3.23x) and asset turnover (1.442x), but constrained by thin net profit margin of 1.6%. Operating margin of 1.4% represents 20 basis points compression from prior period's estimated 1.6%, confirming operational efficiency challenges. Gross profit margin remained at 7.7%, consistent with low-margin pharmaceutical distribution industry characteristics. Basic EPS improved to 439.74 yen from 398.44 yen (YoY +10.4%), though driven substantially by extraordinary gains rather than operational improvement. [Cash Quality] Cash and deposits increased 89.7% YoY to 194.7 billion yen, providing short-term debt coverage of 2.2x against current liabilities of 878.5 billion yen. The cash buildup reflects investment securities sales proceeds contributing to liquidity strengthening. [Investment Efficiency] Total asset turnover of 1.442x indicates efficient asset utilization relative to revenue generation, supported by working capital-intensive distribution operations. Inventory turnover of 132.3 days reflects pharmaceutical product holding patterns, while accounts receivable reached 616.0 billion yen with turnover period of 119 days, signaling collection cycle elongation. [Financial Health] Equity ratio of 31.0% decreased from prior 36.6%, indicating leverage expansion. Current ratio of 118.8% and quick ratio of 99.2% provide adequate short-term liquidity coverage, though below trading industry median of 188%. Debt-to-equity equivalent of 2.23x approaches cautionary thresholds, reflecting aggressive capital structure relative to equity base.
Cash and deposits increased 92.1 billion yen YoY to 194.7 billion yen, representing a substantial 89.7% growth that primarily reflects proceeds from investment securities sales recorded as extraordinary gains of 14.9 billion yen. Working capital changes show accounts receivable expanding 60.3 billion yen to 616.0 billion yen, extending collection cycles to 119 days and absorbing operating cash. Inventory increased 12.0 billion yen to 172.5 billion yen, tied to revenue growth and maintaining turnover at 132.3 days. Accounts payable surged 191.9 billion yen to 827.7 billion yen, indicating extended payment terms to suppliers with payable days reaching 164 days. The substantial payables increase functionally provided financing for working capital needs, though creating potential settlement timing risk. Short-term liquidity position appears adequate with current assets of 1,044.0 billion yen covering current liabilities of 878.5 billion yen at 1.19x. The cash buildup from investment realization strengthens financial flexibility, though operational cash generation sustainability requires monitoring given operating profit decline and working capital elongation.
Ordinary income of 29.3 billion yen versus operating income of 27.2 billion yen shows non-operating net contribution of approximately 2.1 billion yen, representing 0.1% of revenue and indicating minimal reliance on non-operating items at this level. The significant divergence appears between ordinary income (29.3 billion yen) and profit before tax (44.3 billion yen), with extraordinary gains from investment securities sales of 14.9 billion yen contributing 33.6% of pre-tax profit. These gains represent non-recurring factors unlikely to repeat, meaning core operational earnings power approximates the 27-29 billion yen range at ordinary income level. The effective tax rate applied to profit before tax suggests normal tax treatment with net income of 31.0 billion yen representing 70.0% conversion rate, though actual tax payments relative to operating profits warrant scrutiny. While quarterly cash flow statements are not fully disclosed, the 89.7% increase in cash position combined with investment securities sales suggests asset monetization rather than operating cash flow improvement drove liquidity gains. Accounts receivable growth outpacing revenue growth (9.8% versus 2.6%) indicates potential accruals expansion and collection efficiency deterioration, warranting attention to earnings cash conversion quality. Overall earnings quality assessment indicates operating profit weakness masked by non-recurring investment gains, with working capital trends suggesting cash conversion challenges ahead.
Full-year guidance targets revenue of 2,468.0 billion yen (YoY +2.8%), operating income of 33.6 billion yen (-9.5%), ordinary income of 35.1 billion yen (-9.6%), and net income of 32.8 billion yen. Progress rates through Q3 represent 76.4% for revenue, 81.0% for operating income, 83.5% for ordinary income, and 94.6% for net income relative to full-year targets. Revenue progress of 76.4% aligns reasonably with standard 75% expectation for Q3, suggesting no material variance from seasonal patterns. Operating income progress of 81.0% runs ahead of seasonal baseline, though the YoY decline forecast of -9.5% for full year indicates Q4 expectations for continued margin pressure. Net income progress rate of 94.6% substantially exceeds standard 75% benchmark by 19.6 percentage points, reflecting the Q3 extraordinary gains from investment securities sales that are not expected to recur in Q4. This implies anticipated Q4 net income of only 1.7 billion yen, materially below operational run rates, suggesting either conservative Q4 assumptions or absence of further non-recurring gains. The guidance reflects management expectations for continued top-line growth coupled with persistent operational margin compression, requiring attention to cost structure and competitive dynamics in pharmaceutical distribution.
Annual dividend is maintained at 50 yen per share, consistent with prior period levels, comprising interim dividend of 50 yen (actual) and year-end dividend of 50 yen (planned). Based on net income of 31.0 billion yen and average outstanding shares of 70,529 thousand, calculated dividend payout ratio approximates 23.3%, remaining within sustainable range. Treasury stock increased substantially from 0.5 billion yen to 20.7 billion yen during the period, indicating share repurchase activity that absorbed approximately 20.2 billion yen of capital. Combined with estimated total dividends of approximately 3.5 billion yen (50 yen times ~70 million shares), total shareholder returns approach 23.7 billion yen, though share buyback details and timing are not fully disclosed in provided data. Total return ratio incorporating both dividends and buybacks would approximate 76.4% if all treasury stock increases occurred in current period, though this likely reflects multi-period accumulation. Dividend sustainability appears adequate given 23.3% payout ratio and cash position of 194.7 billion yen, though sustainability depends on maintenance of operational cash generation and avoidance of working capital deterioration. Management's dividend policy appears oriented toward stability, with shareholder returns balanced against capital needs for working capital and business investment.
Structural margin compression in pharmaceutical distribution represents the primary operational risk, with operating margin of 1.4% and declining operating income despite revenue growth indicating intensifying pricing pressure and cost inflation. Pharmaceutical wholesale operates with minimal gross margins of 7.7% and faces structural challenges from healthcare cost containment policies, generic drug proliferation, and customer pricing negotiations. Working capital management risk has elevated materially with accounts receivable reaching 119 days and receivables growing 9.8% while revenue grew only 2.6%, suggesting collection cycle elongation and potential credit exposure to medical institutions. Accounts payable surge of 30.2% to 827.7 billion yen provides temporary financing but creates settlement timing risk and potential supply chain relationship strain. Financial leverage risk emerges from debt-to-equity equivalent of 2.23x and equity ratio decline to 31.0%, positioning the company with limited financial flexibility should interest rates rise or operating performance deteriorate further. The balance sheet expansion with total assets reaching 1,307.5 billion yen against equity of only 405.2 billion yen creates vulnerability to asset quality deterioration or valuation adjustments, particularly given inventory of 172.5 billion yen and accounts receivable of 616.0 billion yen representing combined 60.3% of total assets.
[Industry Position] (Reference - Proprietary Analysis)
The company's ROE of 7.7% exceeds the trading industry median of 6.4% (2025-Q3, n=19), positioning in the upper half of industry distribution and above the interquartile range of 2.4-9.9%. Operating margin of 1.4% falls significantly below the industry median of 3.2% (IQR: 1.7-4.9%, n=17), ranking in the lower quartile and confirming structural profitability challenges relative to broader trading sector peers. Net profit margin of 1.6% substantially underperforms the industry median of 2.7% (IQR: 1.3-6.0%, n=19), indicating below-average profitability conversion. The equity ratio of 31.0% trails materially behind the industry median of 46.4% (IQR: 39.6-52.6%, n=19), reflecting more aggressive leverage positioning. Current ratio of 118.8% significantly underperforms the industry median of 188% (IQR: 164-238%, n=15), suggesting tighter liquidity management relative to peers. Asset turnover of 1.442x exceeds the industry median of 1.00x (IQR: 0.62-1.20x, n=19), demonstrating superior asset utilization efficiency characteristic of pharmaceutical distribution's rapid inventory turnover model. Financial leverage of 3.23x exceeds the industry median of 2.13x (IQR: 1.87-2.46x, n=19), confirming above-average leverage usage. Revenue growth of 2.6% YoY underperforms the industry median of 5.0% (IQR: -5.0% to 7.8%, n=19), positioning below mid-point growth expectations. Accounts receivable turnover of 119 days exceeds the industry median of 78.9 days (IQR: 67.5-103.3 days, n=18), indicating collection cycle elongation relative to trading sector norms. Payables turnover of 164 days substantially exceeds the industry median of 77.9 days (IQR: 62.5-98.3 days, n=17), reflecting extended payment terms characteristic of pharmaceutical distribution's working capital model. Overall industry positioning indicates operational efficiency in asset turnover offset by structural margin disadvantages, elevated leverage, and working capital management challenges relative to broader trading sector benchmarks.
(Industry: Trading, Comparison: 2025-Q3 period, Source: Proprietary analysis)
First, the company demonstrates structural profitability challenges inherent to pharmaceutical distribution with operating margins of 1.4% and gross margins of 7.7% remaining compressed despite revenue growth, indicating limited pricing power and competitive intensity requiring operational efficiency improvements to sustain returns. Second, extraordinary gains from investment securities sales of 14.9 billion yen contributed materially to net income growth of 1.1% and elevated profit before tax, representing non-recurring factors that mask underlying operational weakness with operating income declining 8.6% YoY, necessitating focus on core earnings power sustainability. Third, working capital management has deteriorated with accounts receivable expanding to 119-day turnover and growing 9.8% versus 2.6% revenue growth, while accounts payable surged 30.2% to provide temporary financing, creating cash conversion and settlement timing risks that warrant monitoring of operating cash flow generation and collection efficiency trends going forward.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.